Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Denies Epix Appeal, Asks For New Vasovist Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Epix may raise the level of its appeal on the imaging agent to FDA’s Center for Drug Evaluation & Research.

You may also be interested in...



Epix Will Resubmit Vasovist NDA By Mid-Year

End appears near in long road to approval for vascular imaging agent after FDA and Epix agree on plan for Phase III study image re-reads.

Epix Will Resubmit Vasovist NDA By Mid-Year

End appears near in long road to approval for vascular imaging agent after FDA and Epix agree on plan for Phase III study image re-reads.

Epix Pharmaceuticals President Andrew Uprichard: An Interview With “The Pink Sheet” DAILY

Uprichard discusses FDA’s recent encouraging response to Epix’s Vasovist appeal, the regulatory climate for imaging agents, and Epix’s conversion to therapeutics.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel